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Sulllmary 
CTLA4 ligands  are important  costimulatory molecules because soluble CTLA4Ig blocks the 
induction ofT cell responses and induces T cell tolerance. As CTLA4 immunoglobulin (CTLA4Ig) 
binds B7 when the latter is expressed on fibroblasts, it was widely assumed that CTLA4Ig blocks 
T cell costimulation by blocking the function of BT. Here we show that the major costimulatory 
ligand bound by CTLA4Ig (which we term CTLA4 ligand A) on antigen-presenting  cells are 
not encoded by the B7 gene. CTLA4 ligand A also differs from B7 in cellular distribution and 
in the respective levels of expression. Both B7 and CTLA4 ligand A  are critically involved in 
T  cell costimulation. 
C 
ostimulatory molecules are required for induction of T 
cell donal expansion and for prevention of T  cell un- 
responsiveness. Numerous experiments have demonstrated that 
the costimulatory molecules that bind to CTLA4 play a major 
role in T  cell costimulation.  Thus,  the chimeric molecule 
CTLA4Ig,  which is composed of the extracellular domain 
of CTLA4 and the Fc fragment of Ig (1), inhibits T  cell re- 
sponses to anti-CD3 (2), allogeneic MHC (2, 3), and soluble 
proteins (2). In vivo, CTLA4Ig has been shown to inhibit 
T  cell-dependent Ab responses (4) and to prolong survival 
of aUogeneic and xenogeneic grafts (5, 6). More interestingly, 
CTLA4Ig induces specific  T  cell hyporesponsiveness to al- 
logeneic antigen if T cells are stimulated with the allogeneic 
antigen  in  the  presence  of  CTLA4Ig  (7).  In  addition, 
CTLA4Ig induces tolerance for xenogeneic pancreatic grafts 
(5). Thus the ligand(s) for CTLA4Ig is critical both for in- 
duction of the immune response and for prevention of inac- 
tivation  of T  cells. 
CTLA4 can bind to B7/BB1 (hereafter called B7) if the 
latter is expressed on fibroblasts (1). Because of this, it is widely 
assumed that  the molecule that  CLTA4Ig blocks on APC 
is B7 (1-8).  However, the ligand CTLA4 on APC has  not 
been well characterized.  As multiple ligands have been shown 
to bind to one cell surface molecule (9,  10), the costimula- 
tory molecule that binds to CTLA4 may not necessarily be 
B7. Here we report that the major ligand on APC for CTLA4 
(hereafter called CTLA4 ligand A) is distinct from B7. Both 
B7 and the CTLA4 ligand A are expressed on APC and are 
critical  for costimulation  for CD4 T  cell proliferation. 
Materials  and Methods 
Production of  Anti-B7 mAbs.  Antimurine B7 mAbs were gener- 
ated by fusion ofmurine myeloma Ag8,653 with spleen cells from 
hamsters that were immunized with Chinese hamster ovary (CHO)- 
mB7 three times at 2-wk intervals. The hybridoma supematants 
were screened for their ability to bind CHO-mB7 but not CHO 
cells by flow cytometry. 
Proliferation  of  Purified T Cells.  CD4 T cells were purified from 
nonadherent spleen cells from naive CBA/CaJ mice by two rounds 
of treatment  of complement and a cocktail of Abs, including anti- 
Thyl.2 mAb HO13.4.9 (11), anti-CD8 mAb M31 (12), anti-Mac-1 
mAb M1/70.15.11.5H (13), and anti-heat stable antigen (lISA) mAb 
J11d (14). The CD4 T cells were stimulated with anti-CD3  mAb 
2Cl1.145 (15) supernatants  (1:40) and one of the three types of 
accessory cells: COS cells transfected with FcRII (16) and B7, and 
T-depleted spleen cells, all pretreated with mitomycin C, as described 
(17). After 42 h of culture, the cells were pulsed with 1/~Ci/well 
of [3H]TdR for an additional 6 h.  The data shown were means 
of duplicates, with variations <15%. 
Analysis of B7 mRNA by PCR.  mRNA were prepared from 
5  x  106 of either M12.4.1, CH27, or total spleen cells by the fast- 
tract poly A RNA preparation kit (Clontech, Palo  Alto, CA). First 
strand  cDNA were prepared  using  50 ng of hexamer  random 
primers, 1 #g mRNA, 200 U Moloney MuLV reverse transcriptase 
(GIBCO BRL, GA: MD). Similar results were obtained when poly 
dT or B7 reverse primer were used to prepare the first strand cDNA. 
The B7 or glyceraldehyde-3-phosphate dehydrogenase DNA were 
amplified from the cDNA by PCR reaction as has been described. 
The primers used were: B7 forward primer GAAGCTATGGCT- 
TGCAATTGTCAG, B7 reverse primer AGAAGAACTAAAGGA- 
AGACGGTCT, GAPDH forward primer ATGG'IGAAGGTCGGT- 
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AGGTGGAAGAGTGGGAGTTGCTGT. 
Blocking of CTLA4Ig Binding by Anti-B7 mAb 3A12.  CHO- 
mB7, LPS-activated B cells and spleen adherent ceils prepared as 
described were incubated with a given concentration of anti-B7 
mAb 3A12 (this study) for 30 rain at 4~  The cells were then 
incubated with CTLA4Ig (2 t~g/ml)  for 30 rain. The binding of 
CTLA4Ig was detected by FITC-labeled goat anti-hamster IgG 
(Tago, Inc., Burlingame, CA) diluted in I mg/ml of normal ham- 
ster Ig. The data shown, percent maximal binding, was the per- 
centage of CTLA4Ig binding in the absence of blocking Ab,  as 
calculated  by  the  mean  fluorescence  channel  numbers.  Goat 
anti-human IgG diluted with I mg/ml of hamster Ig did not bind 
3A12 significantly,  and this binding has been subtracted. 
Results  and  Discussion 
To address  whether  B7 is the  major ligand  for CTLA4 
on APC, we have generated three antimurine B7 mAbs, 1135, 
3A12,  and  7A5.  All  three  mAbs  bind  B7  and  block  its 
costimuhtory activity (Fig. 1). We have compared the binding 
of CTLA4 to normal spleen cells and LPS-activated B cells 
with that of anti-B7 mAbs. CTLA4Ig gives low but detect- 
able binding  to normal  spleen cells, whereas  three anti-B7 
mAbs fail to bind spleen cells (Fig. 2 a). For activated B ceils, 
CTLA4Ig gives much better binding than the anti-B7 mAbs. 
As  measured  by the peak  fluorescence channel  numbers,  a 
saturating amount of CTLA4Ig binds LPS-activated B cells 
about 20 times as well as anti-B7 mAb (Fig. 2  b), although 
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Figure 2.  Comparative  study  orB7 and  CTLA4 ligand by flow cytom- 
etry. (a) Binding of CTLA4Ig and anti-B7  mAbs to CBA/CaJ spleen  cells. 
The cells were incubated with  either CTLA4Ig  (0.5 /~g/ml, 500,000 
cells/wall in 50/~1), CD48Ig, or a cocktail of three anti-B7 mAbs (3A12, 
1D5, and 7A5). The binding of  CTLA4Ig was detected  with FITC-labeled 
goat anti-human IgG (Accurate  Chemical  and Scientific  Corp., Westbury, 
NY),  whereas the binding  of anti-B7 mAbs was detected with goat 
anti-hamster Ig (Caltag  Laboratories,  South San Francisco,  CA). (b) Binding 
of  anti-B7  mAb 3A12 (10 t~g/ml) and CTLA4Ig (2 t~g/ml)  to LPS-activated 
B cells. Similar results were obtained with mAb 1D5. (c) Blocking of 
CTLA4Ig binding to CHO-mB7 and LPS-activated  B cells by 3A12. (d) 
Blocking of the binding of  CTLA41g  to low density, spleen-adherent  cells. 
This population contains 35%  B220  + cells, 36%  Mac-1  + cells, 32% 
CD11c + cells, and 7% Thyl + cells. 
Figure  1.  Characterization of hamster antimurine B7 mAbs. (a) mAbs 1I)5, 3A12, and 7A5 bind to murine B7-transfected  (CHO-mB7) but not 
untransfected CHO cells, as analyzed  by flow cytometry. (b) Immunoprecipitation analysis of lzSI-labeled  CHO-mB7 cell lysates with antimurine B7 
mAbs. (lane a) Hamster mAb 21F10; (lane b) 11)5; (lane c) 3A12; and (lane d) 7A5.7A5  was used as hybridoma supernatant, whereas other Ig were 
used at 3/~g/sample. (c) Antimurine B7 mAbs block the costimulatory activity of murine B7-transfected COS cells. COS cells (10,000/well) transfected 
with murine B7, FcKII, and B7 +  FcRII are used as accessory  cells for CBA/CaJ CD4 T cells (100,000) stimulated with 1:40 dilution of anti-CD3 
mAb 2Cl1.145 supernatant. 
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Figure  3.  Two-color flow cytometry analysis of the distribution of B7 
and CTLA4Ig ligand on LPS-activated B cells. LPS-activated B cells were 
dually stained with biotinylated anti-B7 mAb 1195 and unlabeled CTLA4Ig. 
The binding of anti-B7 mAb was detected by PE-labeled avidin, and that 
of CTLA4Ig detected by FITC-labeled goat anti-human IgG. Similar results 
were obtained with mAb 3A12. 
both reagents used at saturating concentrations bind CHO 
cells transfected with B7 comparably (data not shown). Anti- 
B7 mAb 3A12 blocks CTLA4 binding to CHO-mB7, but 
not to LPS-activated  B cells (Fig. 2 c), or to low-density spleen 
adherent cells (Fig. 2 d). This differential  blocking of  CTLA4Ig 
binding by anti-B7 mAb on different cell types indicates that 
the majority of the CTLA4 ligand on APC is distinct from 
B7 expressed  on CHO cells. Furthermore, anti-B7 mAbs bind 
only a fraction of LPS-activated B cells that bind CTLA4Ig 
(Fig. 3). Thus, among activated B cells, some cells  only express 
a non-B7 CTLA4Ig ligand, which we call CTLA4 ligand A. 
Cell surface  iodination labels CTLA4 ligand on CHO-mB7 
but not on LPS-activated B cells as assayed by immunopre- 
cipitation  (data not shown). As iodination requires tyrosine 
or histidine in the extraceUular domain, this result raises the 
possibility  that the amino acid composition of CTLA4Ig 
ligand on LPS-activated B cells may be different from B7. 
In other words, CTLA4 ligand A may be encoded by a non- 
B7 gene. Our analysis of B7 mRNA and cell surface expres- 
sion of B7 and CTLA4 ligands on a panel of B lymphoma 
cell lines demonstrates that this  is the case. The results of 
two representative cell lines are shown in Fig. 4. CH27 binds 
both anti-B7  and CTLA4Ig. M12.4.1,  on the other hand, 
binds CTLA4Ig but not anti-B7 (Fig. 4 a). This lack of  binding 
to anti-B7 mAbs was due to a lack of the expression of B7 
molecules,  as  no mRNA for B7  could be detected from 
M12.4.1 by PCR (Fig. 4 b) using three different methods 
to prepare the first-strand cDNA. However, B7 mRNA was 
easily detected from CH27 and spleen cells. Careful titration 
over 1,000-fold range of RNA concentration gives the same 
results (data not shown). Thus CTLA4Ig binds to a cell line 
that does not express B7 gene. These results clearly demon- 
strate that CTLA4 can bind to a ligand other than B7. These 
results also rule out the possibility that the distinction of  B7 
and CTLA4 ligand A revealed by binding studies was due 
to posttranslational  modification  of B7. 
To test the function of CTLA4 ligand A, we compared 
the costimulatory activity of  M12.4.1, which expresses  CTLA4 
ligand A but not B7, with CH27 which expresses both B7 
and CTLA4 ligand A. The accessory cells were fixed before 
addition to T  cells in order to prevent induction of B7 or 
CTLA4 ligand A on the accessory cells by T cells (18-20). 
As shown in Fig. 5 a, both M12.4.1 and CH27 have  costimnla- 
tory activity for CD4 T cells. The costimulatory activity of 
M12.4.1 was blocked completely by CTLA4Ig but not by 
anti-B7 mAb 3A23 (Fig. 5 b). These results demonstrate that 
CTLA4 ligand A is critical for costimulatory activity and 
that CTLA4 ligand A can costimulate T  cell proliferation 
in the absence orB7. To estimate the contribution of  B7 and 
CTLA4 ligand to the costimulatory activity of spleen cells, 
we compared anti-B7 mAb 3A12 with CTLA4Ig in inhibiting 
CD4 T cell proliferation.  3A12 is comparable with CTLA4 
Ig in inhibiting the costimulatory activity of B7 expressed 
on COS cells (Fig. 5 c). However, when spleen APC are used, 
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Figure 4.  M12.4.1  cells  express  no  B7 
mRNA  but  express  CTLA4  ligand A.  (a) 
M12.4.1 or CH27 were incubated with either 
CTLA4Ig  (top)  or  anti-B7  mAb  cocktails 
(bottom)  and their binding detected by FITC- 
labeled goat anti-human IgG or goat anti-ham- 
ster IgG. (Dashed lines) FACS  # profiles of B cells 
incubated with no primary  Ab; (solid li.es) those 
incubated with specific mAbs or chimeric mol- 
ecules. (b) PCR analysis of the expression of 
B7 genes in spleen cells, CH27 and M12.4.1. 
The GAPDH primers were used as internal con- 
trois. PCR products were detected by Southern 
blot using 32P-labeled full-length B7 cDNA, 
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Figure 5.  Contribution ofCTLA4 ligand A to costimulation for CD4 
T cell  pro~tion. (a) Comparison of the costimuhtory activity of M12.4.1 
and CH27.  Varying numbers of fixed CH27  or M12.4.1 cells were in- 
cubated with 5  x  104/well of CD4 T cells and soluble anti-CD3 mAb 
2Cl1.145.  (b) Inhibition  of the costimulatory  activity of M12.4.1 by 
CTLA41g. 5  ~  104/well of CD4 T cells were stimulated with soluble 
anti-CD3 mAb in the presence of 104/well of M12 cells as accessory  cells. 
Var3ang concentrations of CTLA4Ig, anti-B7 mAb 3A12, and CD48Ig 
were added at the beginning of the culture. (a and b) Proliferative  response 
of CD4 T cells were determined by incorporation of pH]TdR into T cells 
at 72 h of culture. (c and d) Inhibition of CD4 T cell proliferation with 
anti-B7 mAb 3A12 and CTLA4Ig. 10Vwell of COS cells transfected  with 
B7 and FcRII (c) or 10S/well of T-depleted spleen cells (d) were used as 
accessory cells. In both c and d,  the accessory cells were treated with 
mitomycin C (100 #g/ml, for 1 h at 37~  before addition to the cuhure 
and the proliferative responses were determined at 48 h of culture. 
CTLA4Ig, which binds both B7 and CTLA4 ligand A, is 
about 50-100-fold more ef~cient in blocking T cell costimu- 
lation (Fig.  5 d). 
These data, taken together, revealed that CTLA4 ligand 
A is the major ligand on APC and is expressed independently 
of the B7 gene. Both CTLA4 ligand A and B7 are critically 
involved in costimulating T  cell proliferation. Our results 
reconcile the widely experienced differences in activity be- 
tween anti-B7 mAbs and CTLA4Ig (19-22) without invoking 
a higher affinity of CTLA4Ig (1). 
Our conclusion has several important implications for un- 
derstanding the molecular basis of T cell costimulation. First, 
much of the function of B7 as deduced from blocking studies 
by CTLA4Ig (1-8)  is likely contributed by both B7  and 
CTLA4 ligand A. The function of B7 as the major costimu- 
lator molecule  needs to be reevaluated. Second, although both 
B7 and CTLA4Ig ligand are involved in T  cell costimula- 
tion, it is not clear at this point whether they serve different 
functions in T  cell costimulation. Whereas B7 binds both 
CTLA4 and CD28, it is not known whether CTLA4 ligand 
A binds CD28, although circumstantial evidence suggests 
that CD28 may also bind to CTLA4 ligand A. Thus, anti- 
B7 mAbs only partially block the binding of lymphocytes 
to CHO cells transfected with CD28 (23). However, the same 
Abs can completely inhibit the binding of B7 to CD28 (8). 
Furthermore, M12 which express CTLA4 ligand A but not 
B7, also enhances the IL-2 production by CD4 T cells (data 
not shown), suggesting that CTLA4 ligand A may have a 
function similar to that documented for B7 (8). Freshly iso- 
lated spleen cells do not express any detectable  amount of 
B7, although a low level CTLA4 ligand A is detected. The 
expression of CTLA4 ligand A on unstimulated APC means 
that CTLA4 ligand A may play a critical role in the initia- 
tion of T cell responses, such as preventing clonal anergy of 
T cells. B7 may play a more critical role in amplification of 
T cell responses. Finally, when professional APC are used, 
multiple costimulatory molecules, such as B7 (1-8),  CTLA4 
ligand A (this study), and HSA (2, 17) are needed for T cell 
responses, because Abs or soluble receptors to any of these 
molecules have been shown to inhibit T  cell proliferation. 
On the other hand, cells that express only one of these mole- 
cules have been shown to costimulate T  cell proliferation. 
This discrepancy  can be explained by the amount of the 
costimulators expressed,  the structure of the costimulator, 
and the kinetics of expression of the costimulatory molecules 
in different cell types. The existence of multiple costimulators 
on APC offers flexibility in regulating costimulatory activity 
of APC. 
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